NCT04414241View on ClinicalTrials.gov

Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

June 25, 2020

Primary Completion Date

November 23, 2020

Study Completion Date

November 23, 2020

Conditions
SARS-CoV-2
Interventions
DRUG

Hydroxychloroquine

A loading dose of 600mg of hydroxychloroquine orally on the first day, followed by 400mg of hydroxychloroquine orally every-other-day and use of standard measures of personal protection provided from the hospital for 8 weeks.

Trial Locations (3)

15082

Hospital Nacional Arzobispo Loayza, Lima

15102

Hospital Cayetano Heredia, Lima

07006

"Centro Médico Naval Cirujano Mayor Santiago Távara", Callao

All Listed Sponsors
lead

Universidad Peruana Cayetano Heredia

OTHER

NCT04414241 - Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19 | Biotech Hunter | Biotech Hunter